Why Has Marijuana Not Been Rescheduled? The Answer Is Obvious, Kinda

Why It Matters

The stalled rescheduling keeps cannabis in the most restrictive federal category, limiting banking, research, and market growth while shaping the political calculus for the 2026 elections.

Key Takeaways

• Trump's exec order to move cannabis to Schedule III remains unimplemented
• DOJ cites ongoing work but offers no timeline for rescheduling
• Republican strategists view cannabis reform as a potential youth‑vote boost
• Democratic split on cannabis policy hampers bipartisan legislative progress
• Attorney General’s signature could finalize rule, but legal challenges likely

Pulse Analysis

The federal rescheduling of marijuana has long been a linchpin for the industry’s quest for legitimacy. Under the Controlled Substances Act, cannabis sits in Schedule I, a classification that bars most banks from providing services and stifles scientific research. President Biden’s earlier push and President Trump’s recent executive order to shift the plant to Schedule III were intended to unlock financing, enable interstate commerce, and align federal policy with the growing state‑legal market, which now generates roughly $45 billion annually in the United States.

Political dynamics are now the primary obstacle. GOP operatives, including Roger Stone, argue that a swift rescheduling could win over younger, libertarian‑leaning voters ahead of the 2026 midterms, turning a traditionally Democratic issue into a Republican win. Yet the Department of Justice, led by an attorney general who appears reluctant to act, has offered no concrete timeline, exposing a rare instance where the president’s directive collides with cabinet autonomy. This internal stalemate underscores the broader challenge of translating executive intent into regulatory action, especially when the issue carries electoral weight.

For businesses, the delay perpetuates uncertainty. Without Schedule III status, cannabis firms continue to face high‑cost cash operations, limited access to credit, and heightened compliance risk. Investors watch the regulatory horizon closely, as a successful rescheduling could trigger a wave of mergers, public listings, and expanded research into therapeutic applications. However, even if the rule is signed, it will likely face administrative and judicial scrutiny, potentially delaying benefits. Stakeholders therefore remain poised, monitoring both the political maneuvering and the legal pathway that will ultimately determine the market’s next growth phase.